On February 3, Huawei announced that five antiviral drugs that may be effective for the 2019 new coronavirus (2019-nCoV) were selected by research institutions such as Huazhong University of Science and Technology and the Chinese Academy of Sciences.
In addition to Huawei Cloud, the research institutions involved in this drug screening are mainly the Basic Medical College of Tongji Medical College of Huazhong University of Science and Technology, Wuhan Children’s Hospital affiliated with Tongji Medical College of Huazhong University of Science and Technology, the First Affiliated Hospital of Xi’an Jiaotong University, and the Beijing Genomics Research Institute of the Chinese Academy of Sciences.
The joint scientific team conducted a super-large-scale computer-assisted drug screening of 8506 drugs that were on the market or in clinical trials for a number of target proteins for the 2019 new coronavirus (of which the Mpro protein crystal structure was provided by the team of academicians) and achieved the first stage of results within a week.
The study found that five drugs may be effective for the 2019 new coronavirus: Beclabuvir, Saquinavir, Bictegravir, Lopinavir and Dolutegravir.
The joint team found that Beclabuvir not only binds to the Mpro protein, but may also be a potential inhibitor of the RNA polymerase NSP12 of the 2019 new coronavirus RNA dependence, and saquinavir not only binds well to the Mpro protein. It can also be combined with the S protein of the 2019 new coronavirus, which can prevent the virus from amplifying both inside the cell and on the surface.
Currently, the joint scientific team is conducting cytological validation of the five antiviral drugs and promoting clinical trials of the drug. The research results released by the joint research team will be open to biomedical research institutions through Huawei Cloud for antiviral drug research and development.